The Study
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
This study is like a fair test where half the people got the real medicine (semaglutide) and half got a fake one (placebo), and nobody knew which they were getting. It shows that the medicine really does lower the chance of heart attacks, strokes, or heart-related death in people with obesity who already have heart disease but not diabetes.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
A special medicine called semaglutide, given as a weekly shot, was tested to see if it helps prevent heart attacks, strokes, or heart-related deaths in people with heart disease and extra weight—but no diabetes.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 574 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The heart benefits are meaningful, especially for high-risk people, but the high rate of side effects leading to stopping treatment is a real concern.
- 2Out of every 100 people, 8 on placebo had a heart problem, but only 6.5 on semaglutide did.
- 3That’s 20% fewer heart problems.
- 4But 16.6 out of 100 stopped the medicine because of side effects, compared to 8.2 on placebo.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The New England journal of medicine
Year
2023
Authors
A. M. Lincoff, K. Brown-Frandsen, H. Colhoun, J. Deanfield, S. Emerson, Sille Esbjerg, S. Hardt-Lindberg, G. Hovingh, S. Kahn, Robert F. Kushner, I. Lingvay, Tugce K Oral, Marie M Michelsen, Jorge Plutzky, C. W. Tornøe, D. Ryan
Related Content
Videos (2)
Claims (3)
If you're obese and have heart disease but not diabetes, taking semaglutide might lower your chances of having a serious heart problem by 20%.
A weekly injection of semaglutide (2.4 mg) helps lower the risk of serious heart problems like heart attack, stroke, or heart-related death by 20% in people over 45 who have heart disease and are overweight, but don’t have diabetes, compared to a fake treatment.
For adults with heart disease and obesity who don’t have diabetes, taking a weekly semaglutide shot (2.4 mg) leads to more than twice as many people stopping treatment because of side effects compared to those taking a dummy shot.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.